Emmaus Life Sciences Names LaVoieHealthScience as Strategic Communications Agency of Record

BOSTON & TORRANCE, Calif.–(BUSINESS WIRE)–#InvestorRelationsLaVoieHealthScience
(LHS), an integrated investor and public relations agency focused on
advancing health and science innovations, today announced that it has
added Emmaus
Life Sciences, Inc.
(Emmaus) to its client roster. LHS provides
strategic communications programming to Emmaus, helping to ensure all
stakeholders – including patients, healthcare practitioners, investors,
and other audiences – are educated and aware of sickle cell disease and
Emmaus’ dedication to patients with this orphan disease.

Emmaus has a history rooted in scientific discovery. Endari™
(L-glutamine oral powder), approved in July 2017, was developed by
Emmaus’ Chairman and CEO Yutaka Niihara, M.D., MPH. Dr. Niihara began
researching the benefits of L-glutamine more than 25 years ago in 1992,
as a physician treating sickle cell patients at the Los Angeles
Biomedical Research Institute at Harbor-UCLA Medical Center. Today, the
company’s product pipeline includes the potential use of L-glutamine to
treat diverticulosis, a GI condition affecting millions, as well as
diabetes. In addition, Emmaus is researching cell-sheet technology for
treatment of limbal stem-cell deficiency, an orphan disease.

“We understand the importance of extending our visibility and building
patient awareness of the treatment options for this debilitating orphan
disease,” commented Kurt Kruger, CFO of Emmaus Life Sciences. “LHS, with
its focus and expertise in the health and life science industry and
connections with influencers, investment community and media make it the
right partner for Emmaus.”

“We are honored to be working with Emmaus, a company led by Dr. Niihara
that is truly passionate about patients and committed to medical
innovation,” said Donna L. LaVoie, President & CEO of
LaVoieHealthScience. “We are aligned with Emmaus’ passion to help
patients afflicted with sickle cell disease and to raise the visibility
of this disease, and the company’s important contributions to this
underserved patient community.”

About Endari™
(L-glutamine oral powder)

Indication
Endari is indicated to reduce the acute
complications of sickle cell disease in adult and pediatric patients 5
years of age and older.

Important Safety Information
The most common adverse
reactions (incidence >10 percent) in clinical studies were constipation,
nausea, headache, abdominal pain, cough, pain in extremities, back pain,
and chest pain.

Adverse reactions leading to treatment discontinuation included one case
each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and
hot flash.

The safety and efficacy of Endari in pediatric patients with sickle cell
disease younger than five years of age has not been established.

For more information, please see full Prescribing Information of Endari
at: www.ENDARIrx.com/PI.

About LaVoieHealthScience
LaVoieHealthScience provides
public relations, investor relations, marketing, and digital
communications to build recognition and value for health science
innovators. The agency has received more than 30 awards during the past
seven years in recognition of the work it has done for its
industry-leading clients and was recently inducted into the 2018 Inc.
5000 Hall of Fame list of Fastest Growing Private Companies.
LaVoieHealthScience represents public and privately-held leaders such as
BIO, Carmell Therapeutics, Emmaus Life Sciences, Landos Biopharma, LEO
Science & Tech Hub, Life Sciences Corridor, NewLink Genetics, Newron
Pharmaceuticals, Origenis GmbH, PathMaker Neurosystems, Scioto
Biosciences, SIRION Biotech, Symbiotix Biotherapies, Triumvira
Immunologics, XenoTherapeutics, Xontogeny LLC, and other emerging health
and science companies. For more information, please visit: https://lavoiehealthscience.com/

Contacts

LaVoieHealthScience
Katie Gallagher, 617-374-8800 x109
Account
Manager, PR and Marketing
kgallagher@lavoiehealthscience.com

leverton

I have been involved with publishing and marketing for the past 32 years. My passion is helping people share their voice. I am able to do this through two important venues: One, with Area-Info.net where people can share everything from opinions to events to news. It is your choice! What do you want to share? Two, through a new program called America's Real Deal I am involved with to help business owners get their voice heard.I schedule speaking engagements with community groups and business groups to share my passion about the importance of "sharing your voice".Contact me directly at lee@leeeverton.coom for scheduling information.